Participant flow

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting · Source last updated 2018-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Pro-netupitant/Palonosetron Dexamethasone

   id

   FG000

   title

   Pro-netupitant/Palonosetron Plus Dexamethasone

2. description

   Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Netupitant/Palonosetron Dexamethasone

   id

   FG001

   title

   Netupitant/Palonosetron Plus Dexamethasone

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         203

      2. group Id

         FG001

         num Subjects

         202

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         120

      2. group Id

         FG001

         num Subjects

         117

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         83

      2. group Id

         FG001

         num Subjects

         85

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice